Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
Yaseen Arabi, Hanan Balkhy, Ali H Hajeer, Abderrezak Bouchama, Frederick G Hayden, Awad Al-Omari, Fahad M Al-Hameed, Yusri Taha, Nahoko Shindo, John Whitehead, Laura Merson, Sameera AlJohani, Khalid Al-Khairy, Gail Carson, Thomas C Luke, Lisa Hensley, Abdulaziz Al-Dawood, Saad Al-Qahtani, Kayvon Modjarrad, Musharaf Sadat, Gernot Rohde, Catherine Leport, Robert Fowler, Yaseen Arabi, Hanan Balkhy, Ali H Hajeer, Abderrezak Bouchama, Frederick G Hayden, Awad Al-Omari, Fahad M Al-Hameed, Yusri Taha, Nahoko Shindo, John Whitehead, Laura Merson, Sameera AlJohani, Khalid Al-Khairy, Gail Carson, Thomas C Luke, Lisa Hensley, Abdulaziz Al-Dawood, Saad Al-Qahtani, Kayvon Modjarrad, Musharaf Sadat, Gernot Rohde, Catherine Leport, Robert Fowler
Abstract
As of September 30, 2015, a total of 1589 laboratory-confirmed cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization (WHO). At present there is no effective specific therapy against MERS-CoV. The use of convalescent plasma (CP) has been suggested as a potential therapy based on existing evidence from other viral infections. We aim to study the feasibility of CP therapy as well as its safety and clinical and laboratory effects in critically ill patients with MERS-CoV infection. We will also examine the pharmacokinetics of the MERS-CoV antibody response and viral load over the course of MERS-CoV infection. This study will inform a future randomized controlled trial that will examine the efficacy of CP therapy for MERS-CoV infection. In the CP collection phase, potential donors will be tested by the enzyme linked immunosorbent assay (ELISA) and the indirect fluorescent antibody (IFA) techniques for the presence of anti-MERS-CoV antibodies. Subjects with anti-MERS-CoV IFA titer of ≥1:160 and no clinical or laboratory evidence of MERS-CoV infection will be screened for eligibility for plasma donation according to standard donation criteria. In the CP therapy phase, 20 consecutive critically ill patients admitted to intensive care unit with laboratory-confirmed MERS-CoV infection will be enrolled and each will receive 2 units of CP. Post enrollment, patients will be followed for clinical and laboratory outcomes that include anti-MERS-CoV antibodies and viral load. This protocol was developed collaboratively by King Abdullah International Medical Research Center (KAIMRC), Gulf Cooperation Council (GCC) Infection Control Center Group and the World Health Organization-International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC-WHO) MERS-CoV Working Group. It was approved in June 2014 by the Ministry of the National Guard Health Affairs Institutional Review Board (IRB). A data safety monitoring board (DSMB) was formulated. The study is registered at http://www.clinicaltrials.gov (NCT02190799).
Keywords: Convalescent plasma; Genome; Intensive care; MERS-CoV; Middle east respiratory syndrome coronavirus; Neutralizing antibodies; Serology; Viral pneumonia.
References
- Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46. doi: 10.1007/s10096-004-1271-9.
- Clopper CJ, Pearson ES. the use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–413. doi: 10.1093/biomet/26.4.404.
- Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828–835. doi: 10.1056/NEJMoa1405858.
- Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456. doi: 10.1093/cid/ciq106.
- Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–473. doi: 10.1378/chest.12-2907.
- Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12:489.
- Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609. doi: 10.7326/0003-4819-145-8-200610170-00139.
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi: 10.1093/infdis/jiu396.
- Müller MA, Meyer B, Corman VM, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15:559–564. doi: 10.1016/S1473-3099(15)70090-3.
- Public Health England (2015) Middle East respiratory syndrome coronavirus (MERS-CoV): clinical management and guidance.
- The World Health Organization (2015) Guidelines on Assessing Donor Suitability for Blood Donation. . Accessed 22 September 2015
- WHO Blood Regulators Network (BRN) (2015) Position Paper on Collection and Use of Convalescent Plasma or Serum as an Element in Middle East Respiratory Syndrome Coronavirus Response. . Accessed 22 September 2015
- World Health Orgnization (2015) Middle East respiratory syndrome coronavirus (MERS-CoV). . Accessed 30 September 2015
- Yeh KM, Chiueh T, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919–922. doi: 10.1093/jac/dki346.
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. doi: 10.1056/NEJMoa1211721.
Source: PubMed